The objective was to perform dosimetry and evaluate dose–response relationships in newly
diagnosed patients with malignant brain tumors treated with direct injections of 131I-labeled …

Purpose: The objective of this study was to perform the dosimetry and evaluate the dose–
response relationships in newly diagnosed patients with malignant brain tumors treated by …

PURPOSE: To assess the efficacy and toxicity of intraresection cavity 131I-labeled murine
antitenascin monoclonal antibody 81C6 and determine its true response rate among …

PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine-131 (131I)–labeled
81C6 antitenascin monoclonal antibody (mAb) administered clinically into surgically created …

We aimed to determine the maximum tolerated dose (MTD) of 131I-labeled 81C6 in patients
with leptomeningeal neoplasms or brain tumor resection cavities with subarachnoid …

INTRODUCTION: The neurohistological findings in patients treated with targeted β emitters
such as 131I are poorly described. We report a histopathologic analysis from patients …

Results from animal experiments have shown that human IgG2/mouse chimeric antitenascin
81C6 (ch81C6) monoclonal antibody exhibited higher tumor accumulation and enhanced …

Aim: None of the established treatments (surgery, radiotherapy, chemotherapy) for
malignant glioma has improved its very poor prognosis. Adjuvant locoregional …

Lack of tumor specificity renders current modalities for treating malignant glioma ineffective.
The administration of 131I-labeled monoclonal antibody (Mab) 81C6, which reacts with the …

The purpose of this study was to determine the feasibility and assess the efficacy and
toxicity, among newly diagnosed malignant glioma patients, of administering 131I-labeled …